CN114081184B - 一种具有预防抑郁和焦虑行为形成的益生菌剂及其应用 - Google Patents
一种具有预防抑郁和焦虑行为形成的益生菌剂及其应用 Download PDFInfo
- Publication number
- CN114081184B CN114081184B CN202111412246.6A CN202111412246A CN114081184B CN 114081184 B CN114081184 B CN 114081184B CN 202111412246 A CN202111412246 A CN 202111412246A CN 114081184 B CN114081184 B CN 114081184B
- Authority
- CN
- China
- Prior art keywords
- probiotic
- lpc45
- depression
- lp3a
- probiotic composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000006041 probiotic Substances 0.000 title claims abstract description 56
- 235000018291 probiotics Nutrition 0.000 title claims abstract description 56
- 230000000529 probiotic effect Effects 0.000 title claims abstract description 52
- 230000015572 biosynthetic process Effects 0.000 title claims description 13
- 230000006400 anxiety behaviour Effects 0.000 title claims description 11
- 239000000203 mixture Substances 0.000 claims abstract description 34
- 241000186012 Bifidobacterium breve Species 0.000 claims abstract description 23
- 241000186605 Lactobacillus paracasei Species 0.000 claims abstract description 23
- 240000006024 Lactobacillus plantarum Species 0.000 claims abstract description 22
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims abstract description 22
- 229940072205 lactobacillus plantarum Drugs 0.000 claims abstract description 22
- 239000000126 substance Substances 0.000 claims abstract description 22
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims abstract description 13
- 150000003271 galactooligosaccharides Chemical class 0.000 claims abstract description 13
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 claims abstract description 12
- 238000002360 preparation method Methods 0.000 claims description 15
- 239000003795 chemical substances by application Substances 0.000 claims description 13
- 239000000284 extract Substances 0.000 claims description 11
- 241000229143 Hippophae Species 0.000 claims description 10
- 235000003145 Hippophae rhamnoides Nutrition 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 9
- 238000004321 preservation Methods 0.000 claims description 9
- 238000011161 development Methods 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 2
- 230000007357 depressive behavior Effects 0.000 claims 1
- 241000894006 Bacteria Species 0.000 abstract description 11
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 abstract description 10
- 230000000968 intestinal effect Effects 0.000 abstract description 9
- 208000019901 Anxiety disease Diseases 0.000 abstract description 7
- 230000000694 effects Effects 0.000 abstract description 7
- 230000036506 anxiety Effects 0.000 abstract description 6
- 230000009286 beneficial effect Effects 0.000 abstract description 6
- 230000036651 mood Effects 0.000 abstract description 6
- 239000002858 neurotransmitter agent Substances 0.000 abstract description 6
- 208000024891 symptom Diseases 0.000 abstract description 4
- 230000035755 proliferation Effects 0.000 abstract description 3
- 230000001105 regulatory effect Effects 0.000 abstract description 3
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 abstract description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 abstract description 2
- 239000002253 acid Substances 0.000 abstract description 2
- 229940099352 cholate Drugs 0.000 abstract description 2
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 abstract description 2
- 230000007413 intestinal health Effects 0.000 abstract description 2
- 239000002243 precursor Substances 0.000 abstract description 2
- 239000013589 supplement Substances 0.000 abstract description 2
- 238000000855 fermentation Methods 0.000 description 34
- 230000004151 fermentation Effects 0.000 description 34
- 239000000843 powder Substances 0.000 description 27
- 241000699666 Mus <mouse, genus> Species 0.000 description 14
- 230000001580 bacterial effect Effects 0.000 description 13
- 239000000725 suspension Substances 0.000 description 12
- 238000002156 mixing Methods 0.000 description 10
- 238000004108 freeze drying Methods 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 230000000052 comparative effect Effects 0.000 description 7
- 238000012258 culturing Methods 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 6
- 229930006000 Sucrose Natural products 0.000 description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 6
- 229940041514 candida albicans extract Drugs 0.000 description 6
- KLOIYEQEVSIOOO-UHFFFAOYSA-N carbocromen Chemical compound CC1=C(CCN(CC)CC)C(=O)OC2=CC(OCC(=O)OCC)=CC=C21 KLOIYEQEVSIOOO-UHFFFAOYSA-N 0.000 description 6
- 239000008103 glucose Substances 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 239000002054 inoculum Substances 0.000 description 6
- WRUGWIBCXHJTDG-UHFFFAOYSA-L magnesium sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Mg+2].[O-]S([O-])(=O)=O WRUGWIBCXHJTDG-UHFFFAOYSA-L 0.000 description 6
- 229940061634 magnesium sulfate heptahydrate Drugs 0.000 description 6
- ISPYRSDWRDQNSW-UHFFFAOYSA-L manganese(II) sulfate monohydrate Chemical compound O.[Mn+2].[O-]S([O-])(=O)=O ISPYRSDWRDQNSW-UHFFFAOYSA-L 0.000 description 6
- 239000011812 mixed powder Substances 0.000 description 6
- 239000003223 protective agent Substances 0.000 description 6
- 238000011218 seed culture Methods 0.000 description 6
- 239000010802 sludge Substances 0.000 description 6
- 239000001632 sodium acetate Substances 0.000 description 6
- 235000017281 sodium acetate Nutrition 0.000 description 6
- 239000005720 sucrose Substances 0.000 description 6
- 239000012138 yeast extract Substances 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000009182 swimming Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 208000036110 Neuroinflammatory disease Diseases 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000003959 neuroinflammation Effects 0.000 description 4
- 238000005192 partition Methods 0.000 description 4
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 3
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 230000037326 chronic stress Effects 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000002068 microbial inoculum Substances 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 235000020183 skimmed milk Nutrition 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000008223 sterile water Substances 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 238000009423 ventilation Methods 0.000 description 3
- 241000186000 Bifidobacterium Species 0.000 description 2
- 241000193403 Clostridium Species 0.000 description 2
- 241000581650 Ivesia Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- VLSOAXRVHARBEQ-UHFFFAOYSA-N [4-fluoro-2-(hydroxymethyl)phenyl]methanol Chemical compound OCC1=CC=C(F)C=C1CO VLSOAXRVHARBEQ-UHFFFAOYSA-N 0.000 description 2
- 239000000935 antidepressant agent Substances 0.000 description 2
- 229940005513 antidepressants Drugs 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 239000008176 lyophilized powder Substances 0.000 description 2
- 230000004630 mental health Effects 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000004088 simulation Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- LQIAZOCLNBBZQK-UHFFFAOYSA-N 1-(1,2-Diphosphanylethyl)pyrrolidin-2-one Chemical compound PCC(P)N1CCCC1=O LQIAZOCLNBBZQK-UHFFFAOYSA-N 0.000 description 1
- 206010002869 Anxiety symptoms Diseases 0.000 description 1
- 241000304886 Bacilli Species 0.000 description 1
- 241001608472 Bifidobacterium longum Species 0.000 description 1
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 208000027534 Emotional disease Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 235000003935 Hippophae Nutrition 0.000 description 1
- 240000000950 Hippophae rhamnoides Species 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 206010040007 Sense of oppression Diseases 0.000 description 1
- 241000589970 Spirochaetales Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000007529 anxiety like behavior Effects 0.000 description 1
- 229940004120 bifidobacterium infantis Drugs 0.000 description 1
- 229940009291 bifidobacterium longum Drugs 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 206010061592 cardiac fibrillation Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000007267 depressive like behavior Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002600 fibrillogenic effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000007358 intestinal barrier function Effects 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/165—Paracasei
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/169—Plantarum
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/519—Breve
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Molecular Biology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Botany (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明公开了一种具有预防抑郁和焦虑行为形成的益生菌剂及其应用,本发明提供的植物乳杆菌Lp3a、副干酪乳杆菌LPC45和短双歧杆菌BB033这3株菌均具有耐酸耐胆盐的特性,可在人体肠道环境中定值繁殖生长,并且这3株菌还可以产生神经递质或其前体物质,例如色氨酸和5‑羟色胺,这些物质能使人产生愉悦情绪,并且低聚半乳糖和低聚异麦芽糖促进有益菌的增殖,使其产生使人愉悦的神经递质,同时益生菌组合物和功能性物质又都可以调节肠道健康,相辅相成,从而达到调节人体情绪的目的,进一步提高了改善抑郁、焦虑症状的作用效果。
Description
技术领域
本发明涉及微生态制剂技术领域,具体涉及一种具有预防抑郁和焦虑行为形成的益生菌剂及其应用。
背景技术
抑郁症是一种发病率和死亡率高的全球性情绪障碍疾病,目前对其致病机理尚不清楚,据世界卫生组织预测,到2030年抑郁症将高居全球疾病负担第一位,抑郁症一线治疗药物以纠正中枢单胺神经递质失调的药物为主,如5-羟色胺再摄取抑制药和5-羟色胺/去甲肾上腺素双重再摄取抑制药等,但这些药物存在反应率低和副作用大等缺点,首发抑郁症患者对这些传统抗抑郁药的响应率只有40-60%,因此,探寻抑郁症新型防治策略是迫在眉睫的任务。
随着越来越多的证据表明肠道微生物在抑郁症和焦虑症发生、发展中扮演了极其重要的角色。譬如,用于诱导啮齿类动物抑郁和焦虑症状形成的慢性应激能够改变肠道菌群丰度,受影响的菌种包括异杆菌、双歧杆菌、土杆菌、梭状杆菌、颤螺菌等,长期摄入植物乳杆菌、长双歧杆菌等益生菌具有显著抑制抑郁和焦虑样行为形成的作用,同时不表现出明显的副作用。此外,婴儿型双歧杆菌也具有显著的抗抑郁特性,神经炎症反应在慢性应激诱导抑郁症和焦虑症形成中具有十分重要的作用,由肠道微生物菌群破坏引起的肠道屏障功能受损是慢性应激导致神经炎症发生的关键病理事件,因此,改善肠道微生物菌群丰度(增加有益菌数量、减少有害菌数量),对缓解由应激引起的神经炎症反应和随之而来的抑郁焦虑等情绪变化具有积极的理论和现实意义。
鉴于现代社会竞争剧烈,在社会和环境双重因素作用下,人群精神健康水平普遍处于亚健康状态,肠道菌群长期紊乱,神经炎症低度长期活跃都是构成情绪障碍疾病形成的关键因素,因此,开发能够改善肠道菌群环境的益生菌对改善人群整体精神健康水平具有重要的社会意义和商业价值。
发明内容
针对现有技术的不足,本发明的目的在于提供一种具有预防抑郁和焦虑行为形成的益生菌剂及其应用,通过改善肠道菌群环境来预防和改善抑郁症状。
为了实现上述目的,本发明采取如下技术方案:
一种具有预防抑郁和焦虑行为形成的益生菌剂,所述益生菌剂由益生菌组合物和功能性物质组成,所述益生菌组合物为植物乳杆菌Lp3a、副干酪乳杆菌LPC45和短双歧杆菌BB033。
优选的,所述益生菌组合物中的总活菌数≥2.0×1011CFU/g。
优选的,所述益生菌组合物中植物乳杆菌Lp3a、副干酪乳杆菌LPC45和短双歧杆菌BB033的质量比为1-2:1-3:1-2。
优选的,所述功能性物质由沙棘提取物、低聚异麦芽糖和低聚半乳糖组成。
优选的,所述沙棘提取物、低聚异麦芽糖和低聚半乳糖的质量比为10:5-8:2-6。
优选的,所述益生菌剂中益生菌组合物的含量为5-20%。
本发明还提供上述益生菌剂在食品、保健品或药品中的应用。
与现有技术相比,本发明具有如下有益效果:
(1)乳杆菌和双歧杆菌均属于常见的益生菌,不同的是本发明提供的植物乳杆菌Lp3a、副干酪乳杆菌LPC45和短双歧杆菌BB033这3株菌均具有耐酸耐胆盐的特性,于胃酸模拟环境下(pH为2-3),这3株菌的存活率为96%,于肠道模拟环境下(pH为7),这3株菌的存活率高达99%,可在人体肠道环境中定值繁殖生长,并且这3株菌还可以产生神经递质或其前体物质,例如色氨酸和5-羟色胺,这些物质能使人产生愉悦情绪,此外,副干酪乳杆菌LPC45还能产生维生素VK,维生素VK可以安神,让人保持心情平和,有效防止焦虑抑郁症状的发生。
(2)本发明提供的低聚半乳糖可作为底物被植物乳杆菌Lp3a、副干酪乳杆菌LPC45和短双歧杆菌BB033利用,可促进有益菌的增殖,同时能够降低肠道pH,抑制有害菌的生长代谢;低聚异麦芽糖含有α-1,6糖苷键,因人体缺少水解α-1,6糖苷键的酶,在胃和小肠内基本不被消化,能被大肠内的有益菌尤其是短双歧杆菌BB033所利用,而大肠杆菌、梭状杆菌等有害菌不能利用,因而具有改善肠道微生态环境的作用;沙棘提取物具有改善抑郁症病人机体多巴胺水平和调节大脑五羟色胺水平的作用,能够调节人体情绪,与益生菌产生的神经递质协同作用,从而改善抑郁得到症状。
(3)本发明提供的益生菌组合物和功能性物质之间具有协同作用,低聚半乳糖和低聚异麦芽糖促进有益菌的增殖,使其产生使人愉悦的神经递质,同时益生菌组合物和功能性物质又都可以调节肠道健康,相辅相成,从而达到调节人体情绪的目的,进一步提高了改善抑郁、焦虑症状的作用效果,本发明的组合物具有温和、无副作用的特点,可有效改善抑郁、焦虑患者的症状。
具体实施方式
以下通过具体较佳实施例对本发明作进一步详细说明,但本发明并不仅限于以下的实施例。
需要说明的是,无特殊说明外,本发明中涉及到的化学试剂均通过商业渠道购买。
植物乳杆菌Lp3a选自江苏新申奥生物科技有限公司,生物保藏信息:CGMCCNo.17054,保藏时间2019.01.02;
副干酪乳杆菌LPC45选自江苏新申奥生物科技有限公司,生物保藏信息:CGMCCNo.22772,保藏时间2021.06.24;
短双歧杆菌BB033选自江苏新申奥生物科技有限公司,生物保藏信息:CGMCCNo.22777,保藏时间2021.06.24。
植物乳杆菌Lp3a冻干菌粉的制备:
(1)液体深层发酵培养
将植物乳杆菌Lp3a保藏菌种以2%接种量接种至用250mL三角瓶装着的150mL种子培养基中,于37℃,5%的CO2培养箱中静置培养,24h后,以3%的接种量接种至用1L三角瓶装着的800mL种子培养基中,于37℃,5%的CO2培养箱中静置培养,培养约7h后,以3%的接种量接种至200mL发酵罐中,内装160mL发酵培养基;
发酵培养条件为:温度37℃,转速50rpm,压力0.05MPa,通风量1.5L/h,发酵过程中pH值用30%的氢氧化钾溶液控制在6.2,待发酵液OD600值和pH值趋于稳定后开始放罐,培养时间为8h,放罐时罐温降至20℃,植物乳杆菌Lp3a发酵液放罐活菌数为1011cfu/mL;
植物乳杆菌Lp3a的种子培养基为:葡萄糖8g/L、蔗糖60g/L、酵母提取物15g/L、乙酸钠8g/L、柠檬酸氢二铵4g/L、七水硫酸镁0.6g/L、一水硫酸锰0.3g/L,pH=6.2;
植物乳杆菌Lp3a的发酵培养基为:葡萄糖10g/L、蔗糖80g/L、酵母提取物40g/L、乙酸钠5g/L、柠檬酸氢二铵2g/L、七水硫酸镁0.58g/L、一水硫酸锰0.25g/L,pH=6.2;
(2)冻干菌剂的制备:待植物乳杆菌Lp3a发酵液温度降至20℃左右时,离心收集菌泥,离心菌体管道降温冷却,离心结束后收得菌泥,然后加入脱脂奶粉1.92kg,乳糖1.12kg,海藻糖0.8kg,抗结块剂0.16kg作为冻干保护剂,用10L无菌水溶解混匀,然后,混合物均匀铺于托盘上,每个托盘装1L,将托盘置于隔板上,在物料中放置温度探头,再进行冻干,收集菌粉,置于-20℃冰箱保存。
副干酪乳杆菌LPC45冻干菌粉的制备:
(1)液体深层发酵培养
将副干酪乳杆菌LPC45保藏菌种以2%接种量接种至用250mL三角瓶装着的150mL种子培养基中,于37℃,5%的CO2培养箱中静置培养,24h后,以3%的接种量接种至用1L三角瓶装着的800mL种子培养基中,于37℃,5%的CO2培养箱中静置培养,培养约7h后,以3%的接种量接种至200mL发酵罐中,内装160mL发酵培养基;
发酵培养条件为:温度37℃,转速50rpm,压力0.05MPa,通风量1.5L/h,发酵过程中pH值用30%的氢氧化钾溶液控制在6.4,待发酵液OD600值和pH值趋于稳定后开始放罐,培养时间为8h,放罐时罐温降至20℃,副干酪乳杆菌LPC45发酵液放罐活菌数为1011cfu/mL;
副干酪乳杆菌LPC45的种子培养基为:葡萄糖8g/L、蔗糖60g/L、酵母提取物15g/L、乙酸钠8g/L、柠檬酸氢二铵4g/L、七水硫酸镁0.6g/L、一水硫酸锰0.3g/L,pH=6.4;
副干酪乳杆菌LPC45的发酵培养基为:葡萄糖10g/L、蔗糖80g/L、酵母提取物40g/L、乙酸钠5g/L、柠檬酸氢二铵2g/L、七水硫酸镁0.58g/L、一水硫酸锰0.25g/L,pH=6.4;
(2)冻干菌剂的制备:待副干酪乳杆菌LPC45发酵液温度降至20℃左右时,离心收集菌泥,离心菌体管道降温冷却,离心结束后收得菌泥,然后加入脱脂奶粉1.92kg,乳糖1.12kg,海藻糖0.8kg,抗结块剂0.16kg作为冻干保护剂,用10L无菌水溶解混匀,然后,混合物均匀铺于托盘上,每个托盘装1L,将托盘置于隔板上,在物料中放置温度探头,再进行冻干,收集菌粉,置于-20℃冰箱保存。
短双歧杆菌BB033冻干菌粉的制备:
(1)液体深层发酵培养
将短双歧杆菌BB033保藏菌种以2%接种量接种至用250mL三角瓶装着的150mL种子培养基中,于37℃,5%的CO2培养箱中静置培养,24h后,以3%的接种量接种至用1L三角瓶装着的800mL种子培养基中,于37℃,5%的CO2培养箱中静置培养,培养约7h后,以3%的接种量接种至200mL发酵罐中,内装160mL发酵培养基;
发酵培养条件为:温度37℃,转速50rpm,压力0.05MPa,通风量1.5L/h,发酵过程中pH值用30%的氢氧化钾溶液控制在6.5,待发酵液OD600值和pH值趋于稳定后开始放罐,培养时间为8h,放罐时罐温降至20℃,短双歧杆菌BB033发酵液放罐活菌数为1011cfu/mL;
短双歧杆菌BB033的种子培养基为:葡萄糖8g/L、蔗糖60g/L、酵母提取物15g/L、乙酸钠8g/L、柠檬酸氢二铵4g/L、七水硫酸镁0.6g/L、一水硫酸锰0.3g/L、0.5gL-半胱氨酸盐酸盐,pH=6.5;
短双歧杆菌BB033的发酵培养基为:葡萄糖10g/L、蔗糖80g/L、酵母提取物40g/L、乙酸钠5g/L、柠檬酸氢二铵2g/L、七水硫酸镁0.58g/L、一水硫酸锰0.25g/L、0.5gL-半胱氨酸盐酸盐,pH=6.5;
(2)冻干菌剂的制备:待短双歧杆菌BB033发酵液温度降至20℃左右时,离心收集菌泥,离心菌体管道降温冷却,离心结束后收得菌泥,然后加入脱脂奶粉1.92kg,乳糖1.12kg,海藻糖0.8kg,抗结块剂0.16kg作为冻干保护剂,用10L无菌水溶解混匀,然后,混合物均匀铺于托盘上,每个托盘装1L,将托盘置于隔板上,在物料中放置温度探头,再进行冻干,收集菌粉,置于-20℃冰箱保存。
实施例1
一种具有预防抑郁和焦虑行为形成的益生菌剂的制备方法,包括如下步骤:
将益生菌组合物和功能性物质混合均匀,即得到益生菌剂,其中益生菌组合物为0.25g植物乳杆菌Lp3a冻干菌粉、0.25g副干酪乳杆菌LPC45冻干菌粉和0.25g短双歧杆菌BB033冻干菌粉的混合菌粉,功能性物质为4.5g沙棘提取物、2.7g低聚异麦芽糖和1.8g低聚半乳糖的混合物。
实施例2
一种具有预防抑郁和焦虑行为形成的益生菌剂的制备方法,包括如下步骤:
将益生菌组合物和功能性物质混合均匀,即得到益生菌剂,其中益生菌组合物为0.2g植物乳杆菌Lp3a冻干菌粉、0.3g副干酪乳杆菌LPC45冻干菌粉和0.2g短双歧杆菌BB033冻干菌粉的混合菌粉,功能性物质为4.5g沙棘提取物、2.7g低聚异麦芽糖和1.8g低聚半乳糖的混合物。
实施例3
一种具有预防抑郁和焦虑行为形成的益生菌剂的制备方法,包括如下步骤:
将益生菌组合物和功能性物质混合均匀,即得到益生菌剂,其中益生菌组合物为0.4g植物乳杆菌Lp3a冻干菌粉、0.6g副干酪乳杆菌LPC45冻干菌粉和0.4g短双歧杆菌BB033冻干菌粉的混合菌粉,功能性物质为4g沙棘提取物、2g低聚异麦芽糖和2g低聚半乳糖的混合物。
实施例4
一种具有预防抑郁和焦虑行为形成的益生菌剂的制备方法,包括如下步骤:
将益生菌组合物和功能性物质混合均匀,即得到益生菌剂,其中益生菌组合物为0.5g植物乳杆菌Lp3a冻干菌粉、0.5g副干酪乳杆菌LPC45冻干菌粉和0.5g短双歧杆菌BB033冻干菌粉的混合菌粉,功能性物质为4g沙棘提取物、2.4g低聚异麦芽糖和1.6g低聚半乳糖的混合物。
对比例1
一种益生菌剂的制备方法,包括如下步骤:
将0.4g植物乳杆菌Lp3a冻干菌粉、0.6g副干酪乳杆菌LPC45冻干菌粉和0.4g短双歧杆菌BB033冻干菌粉混合均匀,即得到益生菌剂。
对比例2
一种益生菌剂的制备方法,包括如下步骤:
将益生菌组合物和功能性物质混合均匀,即得到益生菌剂,其中益生菌组合物为0.6g副干酪乳杆菌LPC45冻干菌粉和0.4g短双歧杆菌BB033冻干菌粉的混合菌粉,功能性物质为4g沙棘提取物、2g低聚异麦芽糖和2g低聚半乳糖的混合物。
对比例3
一种益生菌剂的制备方法,包括如下步骤:
将益生菌组合物和功能性物质混合均匀,即得到益生菌剂,其中益生菌组合物为0.4g植物乳杆菌Lp3a冻干菌粉和0.4g短双歧杆菌BB033冻干菌粉的混合菌粉,功能性物质为4g沙棘提取物、2g低聚异麦芽糖和2g低聚半乳糖的混合物。
小鼠悬尾试验、强迫游泳试验是验证给药后是否具有明显缓解焦虑、抑郁症的常规动物实验。雄性ICR小鼠,18~22g,适应性喂养1周以后,随机分成9组,每组6只,分别喂给本实施例1-4和对比例1-4所制备的益生菌剂,剂量为0.05g/kg,药物用生理盐水配成混悬液灌胃给药,空白对照组在给药期间给与等体积生理盐水。每日1次,连续灌胃给药7天,末次给药1h后进行测试。
小鼠悬尾试验:主要是通过固定小鼠尾部使其头向下悬挂,小鼠在该环境中处于恐慌而拼命挣扎逃跑,又无法逃脱的状态,给小鼠提供一个无法回避的压迫环境,一段时间后,记录处于该环境下的小鼠产生绝望的不动状态过程的不动时间,以观察给药后的治疗效果。将小鼠尾端粘在悬尾箱上部的支架上,将其成为倒吊状态进行悬尾实验,倒挂小鼠的头部距离箱底10cm,一次悬挂6只小鼠,中间用隔板隔开以免碰撞,小鼠在倒挂后由于恐慌会进行挣扎活动,当挣扎疲劳后会处于失望状态而出现间断性不动,悬挂小鼠10分钟,统计后5分钟内悬尾倒挂小鼠累计不动时间;
强迫游泳实验:主要通过将实验小鼠置于一个局限的水中,小鼠在该环境中拼命挣扎试图逃跑又无法逃脱,提供了一个无可回避的压迫环境,一段时间的实验后,小鼠即表现出典型的行为绝望状态的不动状态,记录小鼠产生绝望的不动状态时的不动时间,以观察用药后的治疗效果,将小鼠放入长50cm,宽30cm,高20cm的塑料游泳箱中做强迫性游泳试验,从小鼠放入水中后计时10分钟,记录后5分钟内小鼠的不动时间(指小鼠在水中停止挣扎或显示漂浮状态,仅有微小的肢体运动以保持头部浮在水面),实验结果如下表所示:
组别 | 动物数(n) | 悬尾静止时间(s) | 游泳不动时间(s) |
实施例1 | 6 | 69.34±3.45 | 102.67±1.87 |
实施例2 | 6 | 64.76±2.93 | 103.25±2.41 |
实施例3 | 6 | 58.44±1.57 | 97.58±2.05 |
实施例4 | 6 | 60.21±2.56 | 99.32±1.92 |
对比例1 | 6 | 89.56±1.35 | 114.46±2.73 |
对比例2 | 6 | 101.21±2.27 | 123.35±2.46 |
对比例3 | 6 | 98.62±1.98 | 122.13±1.99 |
空白对照组 | 6 | 127.18±3.26 | 148.33±4.65 |
从表中可以看出,本发明所制备的益生菌剂能够明显减少行为绝望动物模型小鼠中的不动时间,可以确定本发明所制备的益生菌剂具有明显的抗抑郁作用,可用于制备预防抑郁症的药物或保健食品。
最后需要说明的是:以上实施例不以任何形式限制本发明。对本领域技术人员来说,在本发明基础上,可以对其作一些修改和改进。因此,凡在不偏离本发明精神的基础上所做的任何修改或改进,均属于本发明要求保护的范围之内。
Claims (2)
1.一种具有预防抑郁和焦虑行为形成的益生菌剂,其特征在于,所述益生菌剂由益生菌组合物和功能性物质所组成,所述益生菌组合物由植物乳杆菌Lp3a、副干酪乳杆菌LPC45和短双歧杆菌BB033所组成;
其中,植物乳杆菌Lp3a的生物保藏信息为:CGMCC No.17054;
副干酪乳杆菌LPC45的生物保藏信息为:CGMCC No.22772;
短双歧杆菌BB033的生物保藏信息为:CGMCC No.22777;
所述功能性物质由沙棘提取物、低聚异麦芽糖和低聚半乳糖组成;
所述益生菌组合物中的总活菌数≥2.0×1011CFU/g;
所述益生菌组合物中植物乳杆菌Lp3a、副干酪乳杆菌LPC45和短双歧杆菌BB033的质量比为1-2:1-3:1-2;
所述沙棘提取物、低聚异麦芽糖和低聚半乳糖的质量比为10:5-8:2-6;
所述益生菌剂中益生菌组合物的含量为5-20%。
2.如权利要求1所述具有预防抑郁和焦虑行为形成的益生菌剂在制备药品中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111412246.6A CN114081184B (zh) | 2021-11-25 | 2021-11-25 | 一种具有预防抑郁和焦虑行为形成的益生菌剂及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111412246.6A CN114081184B (zh) | 2021-11-25 | 2021-11-25 | 一种具有预防抑郁和焦虑行为形成的益生菌剂及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114081184A CN114081184A (zh) | 2022-02-25 |
CN114081184B true CN114081184B (zh) | 2022-11-11 |
Family
ID=80304477
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111412246.6A Active CN114081184B (zh) | 2021-11-25 | 2021-11-25 | 一种具有预防抑郁和焦虑行为形成的益生菌剂及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114081184B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114774318B (zh) * | 2022-04-19 | 2023-04-25 | 微康益生菌(苏州)股份有限公司 | 一种副干酪乳杆菌在制备缓解焦虑及抑郁症状的产品中的应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111202754A (zh) * | 2019-03-11 | 2020-05-29 | 江苏佰澳达生物科技有限公司 | 一种预防和改善老年痴呆症的益生菌组合物及其应用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1772032B (zh) * | 2005-11-01 | 2011-05-04 | 王敏达 | 沙棘果油和沙棘叶提取物在制备治疗精神抑郁症药物中的应用 |
AU2015337800B2 (en) * | 2014-10-28 | 2021-05-27 | Medlab Ip Pty Ltd | Treatment for depression and depressive disorders |
CN111728111B (zh) * | 2020-06-28 | 2023-01-17 | 武汉康复得生物科技股份有限公司 | 一种缓解焦虑或抑郁的益生菌组合物及其应用 |
CN112999246A (zh) * | 2021-01-22 | 2021-06-22 | 绍兴市第七人民医院 | 一种益生菌组合物及其产品和应用 |
-
2021
- 2021-11-25 CN CN202111412246.6A patent/CN114081184B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111202754A (zh) * | 2019-03-11 | 2020-05-29 | 江苏佰澳达生物科技有限公司 | 一种预防和改善老年痴呆症的益生菌组合物及其应用 |
Also Published As
Publication number | Publication date |
---|---|
CN114081184A (zh) | 2022-02-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111728111B (zh) | 一种缓解焦虑或抑郁的益生菌组合物及其应用 | |
CN108671135B (zh) | 一种调理失眠和抑郁的中药益生菌复合物 | |
JP4846795B2 (ja) | プロバイオティック健康及び体調増進食品、餌及び/又は飲料水添加物並びにその使用 | |
TWI583388B (zh) | 胚芽乳酸桿菌用於製備改善運動表現及降低肌肉疲勞之益生菌組合物之用途 | |
US7785581B2 (en) | Composition and method for reducing feces toxins and treating digestive disorders | |
US20150037286A1 (en) | Use of roseburia in the prevention and treatment for obesity related diseases | |
CN110205270B (zh) | 一种缓解养殖动物便秘的副干酪乳杆菌l9的应用 | |
CN114774313B (zh) | 鼠李糖乳杆菌LRa05在制备缓解便秘制品或调解肠道菌群制品方面的用途 | |
WO2023116227A1 (zh) | 一种具有减肥功效的微生物组合及其应用 | |
US20130022577A1 (en) | Probiotic compositions useful for treatment of bipolar disorder | |
WO2008052468A1 (fr) | Nouvelle souche de lactobacillus rhamnosus, composition pharmaceutique la contenant et ses utilisations, et procede de preparation associe | |
CN114081184B (zh) | 一种具有预防抑郁和焦虑行为形成的益生菌剂及其应用 | |
CN106309506B (zh) | 一种具有调经功能的益生菌组合物及其应用 | |
CN113969253B (zh) | 一株具有便秘治疗效果的乳双歧杆菌jybr-390及其应用和产品 | |
JP6793380B2 (ja) | スクロース摂取による血糖値上昇を抑制する物質の評価方法、スクリーニング方法及び製造方法 | |
CN112263595B (zh) | 罗斯氏菌(Roseburia)在制备防治焦虑症与抑郁症药物中的应用 | |
JP2022530384A (ja) | より高い耐容性および延長された貯蔵寿命のための微生物組成物および方法 | |
CN115011513A (zh) | 一种增强免疫并调解肠胃控制脂肪及减肥排毒的乳酸菌粉 | |
CN113186118B (zh) | 一种用于提高母猪生产性能的复合益生菌制剂及其制备方法 | |
Bhatia et al. | Coencapsulation of synbiotics for the evaluation of in vivo antidiabetic activity | |
CN110628683A (zh) | 一种用于防治鸡腹泻的益生菌复合活菌制剂及其制备方法 | |
CN110839693A (zh) | 吉氏副拟杆菌在预防或治疗肥胖或其相关疾病中的应用 | |
CN112089829B (zh) | 枯草杆菌纤溶酶在治疗功能性便秘药物中的应用 | |
CN113355253B (zh) | 一种动物双歧杆菌及其应用 | |
CN109350629B (zh) | 一种用于治疗酒精戒断综合征的益生菌复合制剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |